Entering text into the input field will update the search result below

Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript)

Mar. 10, 2020 6:29 PM ETExelixis, Inc. (EXEL) Stock
SA Transcripts profile picture
SA Transcripts

Exelixis, Inc. (NASDAQ:EXEL) Barclays Global Healthcare Conference 2020 Call March 10, 2020 3:50 PM ET

Company Participants

Mike Morrissey - Chief Executive Officer

Conference Call Participants

Peter Lawson - Barclays

Peter Lawson

Good afternoon. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the Biotech Analysts at Barclays. It's my great pleasure to introduce Mike Morrissey, CEO of Exelixis. And also, we have Chris Senner, CFO from Exelixis.

Maybe, Mike, just as a general introductory question before we get into the main Q&A section, perhaps you could give us a high-level overview of the company, when your lead drug was approved, and the indications you target. Thank you.

Mike Morrissey

Yes, absolutely. Good afternoon everybody. This is Mike Morrissey. Before I begin today, I'll remind you that I'll be making forward-looking statements today, so please see our SEC filings for a risk -- for a description of the risks that we face in our business.

So Exelixis, commercial stage biotech company, focused in the area of oncology. Our main drug is CABOMETYX, generic name is cabozantinib, which is now a global $1 billion brand based on our 2019 results. Main focus is in kidney cancer. We have labels for really spanning the first and second-line population based on the CABOSUN and METEOR data as well as a second-line HCC label based on the CELESTIAL data.

And then we have a capsule formulation called COMETRIQ that is indicated for a rare form of thyroid cancer called medullary thyroid cancer. So, we're a fully integrated biopharma company with R&D, regulatory, and commercial. We've had a long robust journey and have some very exciting days ahead of us in terms of both 2020 and 2021, with lots of important milestones for cabozantinib and throughout the pipeline that we're building. So Peter, go ahead.

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About EXEL

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on EXEL

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.